190 related articles for article (PubMed ID: 37993930)
1. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
[TBL] [Abstract][Full Text] [Related]
2. Development of super-specific epigenome editing by targeted allele-specific DNA methylation.
Rajaram N; Kouroukli AG; Bens S; Bashtrykov P; Jeltsch A
Epigenetics Chromatin; 2023 Oct; 16(1):41. PubMed ID: 37864244
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
4. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.
Rowland TJ; Bonham AJ; Cech TR
Mol Oncol; 2020 Oct; 14(10):2358-2374. PubMed ID: 33245585
[TBL] [Abstract][Full Text] [Related]
5. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
6. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers.
Esopi D; Graham MK; Brosnan-Cashman JA; Meyers J; Vaghasia A; Gupta A; Kumar B; Haffner MC; Heaphy CM; De Marzo AM; Meeker AK; Nelson WG; Wheelan SJ; Yegnasubramanian S
Cell Oncol (Dordr); 2020 Oct; 43(5):847-861. PubMed ID: 32468444
[TBL] [Abstract][Full Text] [Related]
7. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes.
Stern JL; Paucek RD; Huang FW; Ghandi M; Nwumeh R; Costello JC; Cech TR
Cell Rep; 2017 Dec; 21(13):3700-3707. PubMed ID: 29281820
[TBL] [Abstract][Full Text] [Related]
8. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
9. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085
[TBL] [Abstract][Full Text] [Related]
10. Allele-Specific Epigenome Editing.
Bashtrykov P; Jeltsch A
Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
[TBL] [Abstract][Full Text] [Related]
11. ALV Integration-Associated Hypomethylation at the TERT Promoter Locus.
Lam G; Beemon K
Viruses; 2018 Feb; 10(2):. PubMed ID: 29439385
[TBL] [Abstract][Full Text] [Related]
12. Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
Li X; Qian X; Wang B; Xia Y; Zheng Y; Du L; Xu D; Xing D; DePinho RA; Lu Z
Nat Cell Biol; 2020 Mar; 22(3):282-288. PubMed ID: 32066906
[TBL] [Abstract][Full Text] [Related]
13. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
[TBL] [Abstract][Full Text] [Related]
14. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
15. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
16. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
[TBL] [Abstract][Full Text] [Related]
18. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
19. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
20. Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.
McKelvey BA; Zeiger MA; Umbricht CB
Mol Oncol; 2020 Oct; 14(10):2355-2357. PubMed ID: 32920953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
